Literature DB >> 19949051

Comparative pharmacokinetics of ceftaroline in rats, rabbits, and monkeys following a single intravenous or intramuscular injection.

Yigong Ge1, David Maynard, Douglas E Rickert.   

Abstract

This study assessed the pharmacokinetic profiles for intramuscular and intravenous ceftaroline treatment for rats, rabbits, and monkeys. Ceftaroline, a novel cephalosporin with broad-spectrum activity against Gram-positive and Gram-negative pathogens, demonstrated favorable pharmacokinetic profiles following intramuscular administration in all 3 animal species, comparable to the levels for intravenous dosing. The areas under the plasma concentration-time curve obtained after intramuscular administration were increased in rats and similar in rabbits and monkeys, compared with the levels obtained after intravenous dosing (129%, 7.29%, and 12.7% greater in rats, rabbits, and monkeys, respectively). The data reported here support the development of an intramuscular formulation for ceftaroline.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19949051      PMCID： PMC2812127          DOI： 10.1128/AAC.00645-09

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  12 in total

1.  Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains.

Authors:  Helio S Sader; Thomas R Fritsche; Koné Kaniga; Yigong Ge; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

2.  Therapeutic efficacy of continuous versus intermittent administration of ceftazidime in an experimental Klebsiella pneumoniae pneumonia in rats.

Authors:  R Roosendaal; I A Bakker-Woudenberg; J C van den Berg; M F Michel
Journal:  J Infect Dis       Date:  1985-08       Impact factor: 5.226

3.  Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model.

Authors:  B Vogelman; S Gudmundsson; J Leggett; J Turnidge; S Ebert; W A Craig
Journal:  J Infect Dis       Date:  1988-10       Impact factor: 5.226

4.  Safety, tolerance, and pharmacokinetics of cefepime administered intramuscularly to healthy subjects.

Authors:  R H Barbhaiya; C A Knupp; J Tenney; R R Martin; D J Weidler; K A Pittman
Journal:  J Clin Pharmacol       Date:  1990-10       Impact factor: 3.126

5.  Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models: identification of an in vivo pharmacokinetic-pharmacodynamic target.

Authors:  D Andes; W A Craig
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

6.  A comparative analysis of pharmacokinetics of ceftriaxone in serum and pleural fluid in humans: a study of once daily administration by intramuscular and intravenous routes.

Authors:  A K Goonetilleke; D Dev; I Aziz; C Hughes; M J Smith; G S Basran
Journal:  J Antimicrob Chemother       Date:  1996-12       Impact factor: 5.790

7.  In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.

Authors:  Yigong Ge; Donald Biek; George H Talbot; Daniel F Sahm
Journal:  Antimicrob Agents Chemother       Date:  2008-07-14       Impact factor: 5.191

8.  Impact of dosing intervals on activity of gentamicin and ticarcillin against Pseudomonas aeruginosa in granulocytopenic mice.

Authors:  A U Gerber; W A Craig; H P Brugger; C Feller; A P Vastola; J Brandel
Journal:  J Infect Dis       Date:  1983-05       Impact factor: 5.226

9.  Activity of the new cephalosporin ceftaroline against bacteraemia isolates from patients with community-acquired pneumonia.

Authors:  Ian Morrissey; Yigong Ge; Regina Janes
Journal:  Int J Antimicrob Agents       Date:  2009-02-08       Impact factor: 5.283

10.  Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models.

Authors:  J E Leggett; B Fantin; S Ebert; K Totsuka; B Vogelman; W Calame; H Mattie; W A Craig
Journal:  J Infect Dis       Date:  1989-02       Impact factor: 5.226
View more
  4 in total

1.  Activity of Different Antistaphylococcal Therapies, Alone or Combined, in a Rat Model of Methicillin-Resistant Staphylococcus epidermidis Osteitis without Implant.

Authors:  S Albac; D Labrousse; D Hayez; N Anzala; D Bonnot; P Chavanet; E Aslangul; D Croisier
Journal:  Antimicrob Agents Chemother       Date:  2020-01-27       Impact factor: 5.191

2.  Ceftaroline: A New Cephalosporin with Activity against Methicillin-Resistant Staphylococcus aureus (MRSA).

Authors:  Christopher Duplessis; Nancy F Crum-Cianflone
Journal:  Clin Med Rev Ther       Date:  2011-02-10

3.  Meropenem plus Ceftaroline Is Active against Enterococcus faecalis in an In Vitro Pharmacodynamic Model Using Humanized Dosing Simulations.

Authors:  Jaclyn A Cusumano; Kathryn E Daffinee; Emily C Piehl; Mónica García-Solache; Charlene Desbonnet; Louis B Rice; Kerry L LaPlante
Journal:  Antimicrob Agents Chemother       Date:  2022-09-26       Impact factor: 5.938

4.  Clinical evaluation of the role of ceftaroline in the management of community acquired bacterial pneumonia.

Authors:  Diego J Maselli; Juan F Fernandez; Christine Y Whong; Kelly Echevarria; Anoop M Nambiar; Antonio Anzueto; Marcos I Restrepo
Journal:  Infect Drug Resist       Date:  2012-02-01       Impact factor: 4.003
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.